PE Tech Report


Like this article?

Sign up to our free newsletter

Abris buys Polish healthcare business Scanmed

Abris CEE Mid-Market III LP fund, managed by Abris Capital Partners (Abris), aprivate equity investor focused on Central Europe, is to acquire 100 per cent of the shares in Scanmed – a Poland-based healthcare network operator – from Life Healthcare Group Holdings Limited (Life Healthcare). 

The transaction is subject to regulatory approvals and is expected to close in the first quarter of 2021.

For more than a decade, Scanmed has offered its patients access to comprehensive treatment methods, technologically advanced and high-quality medical equipment and experienced specialists to facilitate their recovery. The company operates in 42 locations across Poland, providing primary healthcare and specialist consultations, advanced diagnostics and hospital treatment. 

Abris was attracted to the healthcare sector by its strong fundamentals, underpinned by a rapidly ageing population in Poland and increasing healthcare spending aimed at improving the quality of service and the comprehensiveness of care. 

Abris plans to support Scanmed in the extension of its service offering and geographical coverage, as well as in the continued improvement of its medical facilities and care in key therapeutic areas. The company also plans to increase commercial revenues in orthopaedics, ophthalmology, rehabilitation and urogynaecology, and to open new labs and surgery units. 

At present, Scanmed operates two multi-specialist hospitals, 13 cardiac centres offering comprehensive diagnostics and cardiological treatment, and a variety of clinics and medical centres across Poland. Scanmed also provides outpatient care services in major Polish cities including Warsaw, Kraków, Poznan, Wroclaw, Gdansk and Pabianice.

Wojciech Łukawski, Partner at Abris Capital Partners, says: “We look forward to working hand in hand with Scanmed’s experienced management team and first-class medical personnel – the key asset of the group – in establishing the company as an institution of choice for Polish patients. We are also privileged to partner with a company that has provided such vital support in tackling the Covid-19 pandemic in Poland, in cooperation with public healthcare institutions.”

Advisors (sell-side): PwC (M&A Lead Advisor, Financial and Tax Due Diligence), and DLA Piper (Legal Advisor). 

Advisors (buy-side): Vienna Capital Partners (M&A Lead Advisor), EY (Financial and Tax Due Diligence), Bain (Commercial Due Diligence), Bureau Veritas (ESG) and Greenberg Traurig (Legal Advisor).

Like this article? Sign up to our free newsletter